About MIRACLE
Chi-Chi Biotech is dedicated to advancing cell therapy from the laboratory to the clinic, using professional technology and a rigorous attitude.
This will open up new possibilities for the clinical application of regenerative medicine.
about Us
Chi-Chi Biotech is a biotechnology company focused on the clinical application of cells and the development of regenerative medicine. With its own cell bank and clinical translation platform as the core, it helps advance cell therapy from the laboratory to the clinic.
We have established a cell bank system that meets international standards. From cell source management, process development, quality control to cryopreservation and release, everything is designed with the requirements of future clinical trials and Investigational New Drug (IND) registration in mind.
Chi-Chi Biotech's first phase focuses on frailty syndrome, developing its own MSC cell therapy product, which received FDA IND approval in June 2026. Simultaneously, leveraging its cell bank and manufacturing capabilities, Chi-Chi also assists pharmaceutical companies and medical institutions in initiating clinical development and registration for other indications.
Vision
The goal is to transform cell therapy from a cutting-edge technology into an affordable, reproducible, and widely clinically applicable treatment option.
Mission
- Establish a safe, stable, and standardized cell bank and process platform.
- We focus on indications with high medical demand and clinical evidence potential, and steadily advance FDA IND and clinical trials.
- We will collaborate with medical institutions, pharmaceutical companies, and research teams in an open and collaborative manner to accelerate the clinical application of regenerative medicine.
Core Team and Collaboration Network
The Chi-Chi Biomedical team combines clinicians, stem cell and immunology researchers, and a management team with corporate governance and industry experience.
We also collaborate with multiple medical centers, research institutions, and industry partners to jointly build a complete network from cell sourcing and preclinical research to clinical trial execution.
As the development project progresses, we continue to invite experts with expertise in regenerative medicine, neuroscience, geriatrics, and new drug regulations to join our advisory team to oversee every clinical development decision.
Quality and compliance are the bottom line for cell therapy.
The safety and quality stability of cell products are the foundation of all clinical development.
Chi-Chi Biomedical uses mainstream international standards as a reference in both cell bank architecture and process design.
We also collaborate with partners who possess GTP/GMP capabilities to develop operational processes that meet practical needs.
Traceability
Everything from donor information and cell batch numbers to cryopreservation records can be tracked.
Consistency
By standardizing processes and release standards, batch-to-batch variations can be reduced.
Safety
Strictly implement risk assessments related to microorganisms, viruses, and tumor formation.
Transparency
Share key quality information with partners to build a foundation of long-term trust.
